NYU will hold its first annual Dual-Energy CT Symposium Oct. 9-10 in New York City. The program is designed for radiologists who have or are considering acquiring a dual-energy scanner, research scientists who are looking to understand current uses of dual-energy CT to stimulate development of translational research projects, and technologists who need a basis in dual-energy terminology and concepts.
NYU will hold its first annual Dual-Energy CT Symposium Oct. 9-10 in New York City. The program is designed for radiologists who have or are considering acquiring a dual-energy scanner, research scientists who are looking to understand current uses of dual-energy CT to stimulate development of translational research projects, and technologists who need a basis in dual-energy terminology and concepts.
Dual-energy CT (DECT) acquisition provides the radiologist with an expanded set of diagnostic capabilities and alters CT imaging in significant ways. Those who have worked with the technology believe it offers significant patient benefit for improved lesion detection, chemical analysis of normal and pathologic tissue, and iodine mapping. Perhaps most significantly, DECT may allow significant patient dose reduction by eliminating noncontrast scanning. Exciting research is currently under way to use the technology in novel ways to analyze treatment responses.
Directed by Dr. Alec J. Megibow, this one-and-a-half-day symposium will bring together clinical physics experts who are currently using both dual- and single-source technology. Attendees will benefit from learning how different approaches to DECT can be used to benefit patient care in all areas of the body. Emphasis will be placed on workflow, integration of DECT software into clinical image evaluation, and highlighting established indications and where research is heading.
To see the full program and register online, click here.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.